Axelopran + Nivolumab for Cutaneous Melanoma

(MORALE-MM Trial)

This trial tests a new treatment combination for individuals with advanced skin cancer (melanoma) that hasn't responded to previous PD-1-based therapies. The study examines the safety and effectiveness of using axelopran, a new potential drug, with nivolumab, which helps the immune system fight cancer. Individuals with melanoma unresponsive to current treatments and not on high doses of opioids might be suitable candidates for this trial. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new potential drug.

The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you are taking more than 30 morphine milligram equivalents of opioids daily or if you are on moderate to strong CYP3A or P-gp inhibitors.

Research has shown that nivolumab is generally well-tolerated by patients with melanoma. In one study, 67.7% of patients experienced treatment-related side effects within 100 days of starting it. These side effects can range from mild to severe, but many patients continue treatment without major issues.

Less information is available about axelopran because it remains in early testing. This trial marks the first time axelopran is combined with nivolumab in humans. Although early results appear promising, the full safety profile is not yet known.

Researchers are excited about the combination of Axelopran and Nivolumab for treating cutaneous melanoma because it brings a fresh approach to therapy. Unlike standard treatments that mostly focus on targeting specific proteins or pathways in cancer cells, Axelopran works by potentially enhancing the immune response when combined with Nivolumab, an immune checkpoint inhibitor. This dual mechanism not only boosts the immune system's ability to attack melanoma cells more effectively but also introduces Axelopran as a novel partner in immunotherapy. By enhancing the body's natural defenses, this combination could offer a more robust and potentially longer-lasting response against melanoma compared to existing treatments.

Studies have shown that nivolumab effectively treats advanced melanoma, achieving impressive long-term survival rates. Research indicates that nivolumab, particularly when combined with ipilimumab, has extended the lives of many patients, with up to 97% surviving ten years in some trials. In this trial, participants will receive a combination of axelopran and nivolumab to determine if axelopran can enhance the immune response in patients whose cancer hasn't responded to other treatments. This combination may enhance nivolumab's effect, offering hope for those with challenging cases of melanoma. Overall, strong evidence supports nivolumab's use in melanoma, and axelopran could be a promising addition.¹⁶⁷⁸⁹